Cellectar Biosciences (NASDAQ:CLRB) Posts Quarterly Earnings Results, Beats Expectations By $0.10 EPS

Cellectar Biosciences (NASDAQ:CLRB) released its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.10, FiscalAI reports.

Here are the key takeaways from Cellectar Biosciences’ conference call:

• Cellectar said site activation is progressing for the confirmatory Phase III trial of iopofosine in relapsed/refractory Waldenström’s macroglobulinemia, with first-patient dosing targeted for Q1 2027. The company is targeting an NDA submission in the first half of 2027 and believes U.S. commercialization could begin as early as late 2027 or early 2028, pending approval.
• A subgroup analysis of patients treated immediately after BTK-inhibitor therapy showed an 87.5% overall response rate, a 79.2% major response rate and a median duration of response of 16 months. These results are from the CLOVER-WaM study and are not confirmatory trial results.
• The company initiated a Phase I-B dosimetry study expected to enroll 20–30 patients, including newly diagnosed and relapsed WM patients, to assess drug uptake and gather additional safety and efficacy data. Cellectar sees potential to inform development in earlier treatment lines, but those benefits remain to be demonstrated.
• Cellectar ended the quarter with $24.6 million in cash and said its runway extends into Q2 2027, while its NDA target is the first half of 2027. Quarterly R&D expense rose to $5.4 million from $2.5 million a year earlier, and net loss widened to $8.0 million from $4.4 million.
• Cellectar plans to delay its European marketing-authorization submission by about nine months, saying it wants U.S. review and pricing discussions to advance first to reduce potential effects on U.S. pricing. The change preserves its preferred sequencing but pushes back the European filing.

Cellectar Biosciences Stock Down 2.0%

Shares of NASDAQ CLRB traded down $0.02 during mid-day trading on Wednesday, reaching $1.20. 4,653 shares of the company were exchanged, compared to its average volume of 357,513. The stock has a market cap of $11.30 million, a price-to-earnings ratio of -0.31 and a beta of 0.65. Cellectar Biosciences has a 1 year low of $1.11 and a 1 year high of $4.70. The firm has a 50-day moving average of $1.70 and a 200 day moving average of $2.56.

Wall Street Analyst Weigh In

CLRB has been the topic of a number of research reports. Wall Street Zen downgraded shares of Cellectar Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cellectar Biosciences in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $11.00.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc. (NASDAQ: CLRB) is a clinical-stage biopharmaceutical company focused on developing targeted radiotherapeutics and oncology treatments. Its technology platform uses phospholipid ether compounds, which are designed to preferentially accumulate in cancer cells and other diseased tissues while limiting exposure to healthy tissue. The company’s leading product candidate is iopofosine I 131, also known as CLR 131, a small-molecule radiopharmaceutical being studied for the treatment of hematologic malignancies, including relapsed or refractory multiple myeloma and certain types of lymphoma.